ColonAI is a technology company.
ColonAI has raised $30K across 1 funding round.
ColonAI has raised $30K in total across 1 funding round.
ColonAI has raised $30K in total across 1 funding round.
ColonAI's investors include Health Wildcatters.
ColonAI is an early-stage technology company founded in 2018 that develops AI-powered software tools to assist gastroenterologists in detecting and treating colorectal tumors during colonoscopies.[1][3] Its flagship products—PolypSense, which highlights suspicious areas and covers blind spots, and PolypSect, which defines tumor margins for complete resection—integrate into existing workflows to improve screening efficiency for colorectal cancer (CRC), a leading cause of cancer deaths affecting nearly 145,000 people annually in the US.[1][3] Targeting physicians performing over 19 million colonoscopies yearly, ColonAI addresses detection misses by leveraging AI vision systems, with early validation from 95% of interviewed gastroenterologists confirming the need.[1][3] The company has raised $30K in seed funding from Health Wildcatters, remains in seed stage, and employs a small team of about 3, headquartered in New York.[1][2]
ColonAI was founded in 2018 by two Columbia University biomedical engineering alumni, Nitya Bansinath and Devansh Nye, who launched the startup to combat CRC using AI-driven imaging.[3][5] Motivated by personal high-risk factors—Bansinath herself is at elevated risk—and the statistic that CRC causes 9% of US cancer deaths, the duo aimed to create equitable, accessible healthcare solutions.[3] The idea emerged from their engineering expertise, evolving into a platform validated through Columbia's entrepreneurship programs: they won first place ($25K) in the Spring 2021 Startup Columbia challenge and placed in the top 24 of the inaugural Columbia-CareOne Healthcare Challenge from over 100 entrants.[3][5] Early traction included strong physician feedback, propelling the company from concept to product development with backing from Health Wildcatters.[1][3]
ColonAI rides the AI in digital health wave, specifically computer vision for gastrointestinal diagnostics amid rising CRC incidence and adenoma miss rates during routine screenings.[1][3][6] Timing aligns with market forces like expanding polyp image datasets (e.g., millions used in tools like GI Genius) and evidence that AI boosts detection by 1% per percentage point increase, potentially cutting cancer risk by 3%—critical as CRC remains the third-leading cancer killer.[3][6] It influences the ecosystem by advancing artificial intelligence and digital health collections, competing in a space with players like Docbot (Y Combinator-backed) while filling gaps in real-time tumor margin tools.[1][4] Broader adoption of similar tech (e.g., Virtua Health's 2023 rollout) underscores regulatory tailwinds and hospital demand for AI to enhance human oversight, positioning ColonAI in a $10B+ endoscopy AI market.[6]
ColonAI's niche focus on polyp detection and resection positions it for growth in AI-augmented endoscopy, potentially scaling via partnerships with health systems or larger medtech firms amid clinician-validated demand.[1][3][6] Upcoming trends like larger training datasets, FDA-cleared modules (e.g., GI Genius precedents), and CRC screening mandates will accelerate adoption, though limited funding ($30K, last raised 4 years ago) signals need for fresh capital to reach clinical trials or commercialization.[1] Its influence may evolve from Columbia incubator darling to key player in reducing CRC mortality, especially if it secures Series A amid booming health AI investments—watch for traction updates on colonai.com.[1][2][3] This seed-stage innovator exemplifies how biomedical engineering alumni are humanizing high-stakes cancer care through precise AI tools.[3]
ColonAI has raised $30K across 1 funding round. Most recently, it raised $30K Seed in September 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2020 | $30K Seed | Health Wildcatters |